These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 26424664)

  • 1. Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors.
    Passeri D; Camaioni E; Liscio P; Sabbatini P; Ferri M; Carotti A; Giacchè N; Pellicciari R; Gioiello A; Macchiarulo A
    ChemMedChem; 2016 Jun; 11(12):1219-26. PubMed ID: 26424664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The kinase polypharmacology landscape of clinical PARP inhibitors.
    Antolin AA; Ameratunga M; Banerji U; Clarke PA; Workman P; Al-Lazikani B
    Sci Rep; 2020 Feb; 10(1):2585. PubMed ID: 32066817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
    Gunderson CC; Moore KN
    Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olaparib, PARP1 inhibitor in ovarian cancer.
    Marchetti C; Imperiale L; Gasparri ML; Palaia I; Pignata S; Boni T; Bellati F; Benedetti Panici P
    Expert Opin Investig Drugs; 2012 Oct; 21(10):1575-84. PubMed ID: 22788971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olaparib for the treatment of ovarian cancer.
    Bornstein E; Jimeno A
    Drugs Today (Barc); 2016 Jan; 52(1):17-28. PubMed ID: 26937492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
    Miller RE; Ledermann JA
    Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP Inhibitors in Ovarian Cancer.
    Mittica G; Ghisoni E; Giannone G; Genta S; Aglietta M; Sapino A; Valabrega G
    Recent Pat Anticancer Drug Discov; 2018; 13(4):392-410. PubMed ID: 29512470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Novel Apigenin-Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer.
    Long H; Hu X; Wang B; Wang Q; Wang R; Liu S; Xiong F; Jiang Z; Zhang XQ; Ye WC; Wang H
    J Med Chem; 2021 Aug; 64(16):12089-12108. PubMed ID: 34404206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olaparib (Lynparza) for advanced ovarian cancer.
    Med Lett Drugs Ther; 2016 Feb; 58(1489):e32-3. PubMed ID: 26938702
    [No Abstract]   [Full Text] [Related]  

  • 11. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
    Liu JF; Matulonis UA
    Curr Oncol Rep; 2016 May; 18(5):29. PubMed ID: 26984416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of novel phthalazinone derivatives as potent poly(ADP-ribose)polymerase 1 inhibitors.
    Xin M; Sun J; Huang W; Tang F; Liu Z; Jin Q; Wang J
    Future Med Chem; 2020 Oct; 12(19):1691-1707. PubMed ID: 33012191
    [No Abstract]   [Full Text] [Related]  

  • 13. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
    Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
    Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.
    Nirsimloo R; Gourley C
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):597-603. PubMed ID: 27115428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others.
    Chen Y; Du H
    Biomed Pharmacother; 2018 Mar; 99():552-560. PubMed ID: 29895102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.
    Wang YQ; Wang PY; Wang YT; Yang GF; Zhang A; Miao ZH
    J Med Chem; 2016 Nov; 59(21):9575-9598. PubMed ID: 27416328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
    Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
    Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1).
    Zhang Z; Chang X; Zhang C; Zeng S; Liang M; Ma Z; Wang Z; Huang W; Shen Z
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1606-1615. PubMed ID: 32779949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer.
    De Jaeghere E; Vandecasteele K; Claes K; Makar A; Tummers P; Cocquyt V; Denys H
    Acta Clin Belg; 2017 Feb; 72(1):6-11. PubMed ID: 27267353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New drug approval: Olaparib and niraparib - first line in ovarian cancer].
    Delaye M; Rodrigues M
    Bull Cancer; 2021 Apr; 108(4):350-351. PubMed ID: 33641880
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.